{"podcast":{"title":"Blood Cancer Talks","slug":"blood-cancer-talks-5570002","podcast_index_feed_id":5570002,"rss_url":"https://feeds.transistor.fm/bloodcancertalks","website_url":null,"image_url":"https://img.transistorcdn.com/W_5G4oA5kAcf9vixuJQw-sMFE98Hvnnp4pex_BzuYvE/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9zaG93/LzMyMDc4LzE2NTcz/MTQxMDUtYXJ0d29y/ay5qcGc.jpg","author":"Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff","episode_count":75,"summary":"This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth. Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston Tweet your suggestions and feedback to @rajshekharucms @AshKishtagari @Eddie_Cliff @BloodCancerTalk","last_synced_at":"2026-09-03T22:19:58.611204+00:00","page_url":"https://stenobird.com/podcast/blood-cancer-talks-5570002"},"episode":{"title":"Episode 51. Venetoclax in AML with Dr. Andrew Wei","slug":"episode-51-venetoclax-in-aml-with-dr-andrew-wei","published_at":"2024-09-27T11:00:00+00:00","page_url":"https://stenobird.com/podcast/blood-cancer-talks-5570002/episode-51-venetoclax-in-aml-with-dr-andrew-wei","show_page_url":"https://stenobird.com/podcast/blood-cancer-talks-5570002","url":"https://share.transistor.fm/s/4ad375ba","audio_url":"https://media.transistor.fm/4ad375ba/cde8ab68.mp3","summary":"In this episode, we discuss the history of venetoclax in AML, along with key clinical trials that have shaped its current use in AML. Here are the trials discussed in this episode: 1. VIALE-A study: https://www.nejm.org/doi/full/10.1056/NEJMoa2012971 2. 10 day Decitabine plus venetoclax for ND AML https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(20)30210-6/abstract 3. Genetic Risk Stratification and Outcomes with AML treated with venetoclax and azacitidine https://ashpublications-org.proxy.library.vanderbilt.edu/blood/article/doi/10.1182/blood.2024024944/517355/Genetic-Risk-Stratification-and-Outcomes-Among 4. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations https://ashpublications-org.proxy.library.vanderbilt.edu/blood/article/doi/10.1182/blood.2024025409/517356/Genetic-risk-classification-for-adults-with-AML 5. AGILE study: Ivosidenib and azacitidine in IDH1-mutated AML https://www.nejm.org/doi/full/10.1056/NEJMoa2117344 6. MRD response and prognosis in treatment naïve AML with AZA/VEN https://ascopubs.org/doi/10.1200/JCO.21.01546?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed 7. Monocytic subclone confer resistance to venetoclax-based therapy in patients with AML https://aacrjournals.org/cancerdiscovery/article/10/4/536/2403/Monocytic-Subclones-Confer-Resistance-to 8. VEN/DEC vs 7+3 https://ashpublications.org/blood/article/142/Supplement%201/970/503790/Comparing-the-Efficacy-and-Safety-of-Venetoclax 9. FILO study: Outcomes of AML https://onlinelibrary.wiley.com/doi/10.1002/ajh.27417 10. Treatment-free remission after ceasing venetoclax-based therapy in patients with AML https://ashpublications-org.proxy.library.vanderbilt.edu/bloodadvances/article/6/1…","meta_description":"In this episode, we discuss the history of venetoclax in AML, along with key clinical trials that have shaped its current use in AML. Here are the trials…","key_points":[],"chapters":[],"topics":[],"duration_seconds":3417,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/blood-cancer-talks-5570002/episodes/episode-51-venetoclax-in-aml-with-dr-andrew-wei/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/blood-cancer-talks-5570002/episode-51-venetoclax-in-aml-with-dr-andrew-wei.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}